Advertisement
Advertisement
ARCT
Arcturus Therapeutics Holdings Inc. Common Stock
9.22
USDSponsored
+0.32
+3.60%
May 08, 16:00 UTC -4
Closed
After-Market
9.13
-0.09
-0.92%
ARCT Earnings Reports
Positive Surprise Ratio
ARCT beat 26 of 41 last estimates.
63%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$6.68M
/-$1.12
Implied change from Q1 26 (Revenue/ EPS)
+224.25%
/+17.89%
Implied change from Q2 25 (Revenue/ EPS)
-76.40%
/+229.41%
Arcturus Therapeutics Holdings Inc. Common Stock earnings per share and revenue
On May 07, 2026, ARCT reported earnings of -0.95 USD per share (EPS) for Q1 26, beating the estimate of -1.11 USD, resulting in a 14.45% surprise. Revenue reached 2.06 million, compared to an expected 7.38 million, with a -72.08% difference. The market reacted with a +3.60% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -1.12 USD, with revenue projected to reach 6.68 million USD, implying an increase of 17.89% EPS, and increase of 224.25% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Iovance Biotherapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.19
Surprise
-24.35%
Corvus Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-2.95%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
Ginkgo Bioworks Holdings, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.09
Actual
-$1.28
Surprise
-17.35%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Codexis, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+28.26%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
PTC Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.03
Surprise
+93.75%
Scholar Rock Holding Corporation Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.81
Actual
-$0.83
Surprise
-1.62%
FAQ
What were Arcturus Therapeutics Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Arcturus Therapeutics Holdings Inc. Common Stock reported EPS of -$0.95, beating estimates by 14.45%, and revenue of $2.06M, -72.08% below expectations.
How did the market react to Arcturus Therapeutics Holdings Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 3.6%, changed from $8.90 before the earnings release to $9.22 the day after.
When is Arcturus Therapeutics Holdings Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Arcturus Therapeutics Holdings Inc. Common Stock's next earnings report?
Based on 8
analysts, Arcturus Therapeutics Holdings Inc. Common Stock is expected to report EPS of -$1.12 and revenue of $6.68M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement